Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance.

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance.
复制标题

DOI:
10.3390/biomedicines10051130
复制
发表时间:
2022-05-13
期刊:
影响因子:
4.7
通讯作者:
--
中科院分区:
工程技术3区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

免疫检查点阻断(ICBs)彻底改变了癌症治疗。最近的研究已经揭示了三阴性乳腺癌(TNBC)的子集被认为是免疫原性乳腺癌亚型。TNBC的特征,如较高的突变率和肿瘤浸润免疫细胞的数量,提供了免疫原性表型。因此,TNBC在临床上对ICB如atezolizumab和pembrolizumab表现出持久的应答。然而,相当数量的TNBC患者没有从这些疗法中获益,并且对耐药机制知之甚少。在这里,我们回顾了生物标志物,预测的反应性TNBCs ICB和最近的进展,描绘耐药的分子机制ICB。
Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating immune cells, render the immunogenic phenotypes. Consequently, TNBCs have shown durable responses to ICBs such as atezolizumab and pembrolizumab in clinic. However, a significant number of TNBC patients do not benefit from these therapies, and mechanisms of resistance are poorly understood. Here, we review biomarkers that predict the responsiveness of TNBCs to ICB and recent advances in delineating molecular mechanisms of resistance to ICBs.
DOI: 10.1016/j.celrep.2015.04.031
发表时间: 2015-05-19
期刊: Cell reports
影响因子: 8.8
作者:
Corrales L;Glickman LH;McWhirter SM;Kanne DB;Sivick KE;Katibah GE;Woo SR;Lemmens E;Banda T;Leong JJ;Metchette K;Dubensky TW Jr;Gajewski TF
通讯作者: Gajewski TF
DOI: 10.1158/0008-5472.can-20-1818
发表时间: 2021-02-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Falvo, Paolo;Orecchioni, Stefania;Bertolini, Francesco
通讯作者: Bertolini, Francesco
DOI: 10.1016/j.ccell.2018.01.011
发表时间: 2018-03-12
期刊: CANCER CELL
影响因子: 50.3
作者:
Costa, Ana;Kieffer, Yann;Mechta-Grigoriou, Fatima
通讯作者: Mechta-Grigoriou, Fatima
DOI: 10.1016/j.cell.2015.09.033
发表时间: 2015-10-08
期刊: Cell
影响因子: 64.5
作者:
Ciriello G;Gatza ML;Beck AH;Wilkerson MD;Rhie SK;Pastore A;Zhang H;McLellan M;Yau C;Kandoth C;Bowlby R;Shen H;Hayat S;Fieldhouse R;Lester SC;Tse GM;Factor RE;Collins LC;Allison KH;Chen YY;Jensen K;Johnson NB;Oesterreich S;Mills GB;Cherniack AD;Robertson G;Benz C;Sander C;Laird PW;Hoadley KA;King TA;TCGA Research Network;Perou CM
通讯作者: Perou CM
DOI: 10.1186/s12885-018-4441-3
发表时间: 2018-05-11
期刊: BMC cancer
影响因子: 3.8
作者:
Bates JP;Derakhshandeh R;Jones L;Webb TJ
通讯作者: Webb TJ